<div id="readability-page-1"><p>TD Cowen analyst Stacy Ku maintained a Buy rating on VYNE Therapeutics today and set a price target of $2.00.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Ku covers the Healthcare sector, focusing on stocks such as BioCryst, KalVista Pharmaceuticals, and LENZ Therapeutics. According to TipRanks, Ku has an average return of <span>13.1%</span> and a 60.34% success rate on recommended stocks. </p> <p>Currently, the analyst consensus on VYNE Therapeutics is a Moderate Buy with an average price target of $2.00.</p></div>

VYNE

<p>TD Cowen analyst Stacy Ku has maintained a Buy rating on VYNE Therapeutics, setting a price target of $2.00. Ku, who focuses on the Healthcare sector, has an average return of 13.1% and a 60.34% success rate on recommended stocks. The current analyst consensus on VYNE Therapeutics is a Moderate Buy, with an average price target also at $2.00.</p>

VYNE Therapeutics (VYNE) Gets a Buy from TD Cowen